One day we hope to be able to say — well, here’s a disease, and then click a button and out pops the design for a drug to ...

Google DeepMind's moonshot, Isomorphic Labs, is gearing up to launch its first ever human trial of AI-designed drugs. The ...

Alphabet’s Isomorphic Labs is preparing to begin human trials of a drug designed using AI, based on protein modelling ...

Alphabet’s Isomorphic Labs, spun out of DeepMind, is preparing to start human trials of AI-designed drugs after raising $600 ...

In an interview with Fortune, Isomorphic Labs president Colin Murdoch shared that four years after its founding, the company ...

Out to make a bigger difference, Alphabet’s Isomorphic Labs is exploring a much more useful application of AI. The Google ...

Founded in 2021, Isomorphic Labs is a subsidiary of Google parent Alphabet. It is currently preparing to dose the first patients with the AI-engineered drug in clinical trials and is “staffing up” ...

Google DeepMind CEO Demis Hassabis has said that AI can have a serious crack at solving all diseases in the coming years. And ...

Google DeepMind's Isomorphic Labs is preparing for human trials of AI-designed drugs, marking a significant advancement in ...

Isomorphic Labs, a subsidiary of Alphabet Inc., is close to human trials for its AI-designed medicines. Other companies are ...

Isomorphic Labs is setting up an office in Cambridge, Mass., as it prepares for clinical trials of some of its AI-enabled drug candidates.

As Isomorphic Labs aims its artificial intelligence tools at drug development, it’s setting up a new outpost in the biotech hub of Cambridge.